Welcome to Diurnal

Pharmaceutical company focused on chronic endocrine diseases

Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.

bio image

Overview

Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency. Diurnal has published details of its transfers of value required under the ABPI Code on the ABPI website and on this website.

Clinical Trial Data Access Request

Diurnal is committed to public disclosure and transparency of our clinical study data. Diurnal is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website www.clinicaltrials.gov. Qualified scientific and medical researchers may request clinical trial data. Diurnal agrees to share patient- and study-level data and protocols from clinical trials in patients, for medicines and indications approved by national regulatory authorities.

Diurnal Limited (Company Number: 05237326) is registered in England & Wales. Registered office: Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, UK.